Biomarkers or pathway signatures of SRC activation following MEK inhibition may predict those patients who would benefit from a SRC‐MEK inhibitor combination to promote the durability of responses to primary MEK inhibitor therapy in patients with KRAS mutant CRC. This evidence concerns the gene SRC and colorectal carcinoma.